Last updated: August 1, 2025
Introduction
NDC 51672-4069 corresponds to Brodalumab (Siliq), a prescription biologic medication approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and other inflammatory conditions. As a monoclonal antibody targeting interleukin-17 receptor A (IL-17A), Brodalumab represents a significant therapeutic advancement, bolstered by its unique mechanism of action.
This market analysis synthesizes current industry trends, regulatory environments, competitive landscapes, and pricing strategies to project future market positioning and pricing trajectories for Brodalumab, with the aim of enabling stakeholders to make data-driven decisions.
Market Context and Therapeutic Landscape
Current Market Dynamics
The biologic segment for psoriasis and inflammatory diseases has seen substantial growth over the past decade, driven by advances in targeted therapies, improved patient outcomes, and expanding indications. Brodalumab entered a competitive market dominated by established biologics such as Adalimumab (Humira), Etanercept (Enbrel), Secukinumab (Cosentyx), and Ixekizumab (Taltz).
Despite competition, Brodalumab distinguishes itself through its fast onset and efficacy, especially in difficult-to-treat psoriasis cases. However, concerns about safety — notably, its boxed warnings related to suicidal ideation and behavior — influence prescribing patterns and reimbursement policies.
Regulatory and Reimbursement Environment
The drug received FDA approval in 2017. Since then, payers' coverage policies have been shaped by post-marketing safety data and real-world efficacy reports. Due to its safety profile, some payers impose strict utilization controls, which impact access and sales volumes.
Market Penetration and Patient Demographics
Current utilization remains modest relative to leaders like Humira and Cosentyx, primarily restricted to specific patient subsets where other therapies are contraindicated or ineffective. The estimated total nationwide eligible patient population approximates 1.5 million individuals with moderate-to-severe plaque psoriasis in the U.S., with a subset likely to be prescribed Brodalumab over the next five years considering formulary evolutions and clinical guidelines.
Price Analysis and Projections
Current Pricing Landscape
As of 2023, the list price of Brodalumab (Siliq) is approximately $7,200 to $7,300 per month for an adult dose, translating to an annual cost of roughly $86,400 to $87,600. This pricing aligns with other IL-17 inhibitors, reflecting the premium status of biologic therapies.
Net pricing—what payers and patients pay after rebates and discounts—varies widely, influenced by negotiated contracts, formulary status, and patient assistance programs. Industry estimates suggest net prices hover around $4,500 to $5,500 per month.
Market Drivers Influencing Price Trends
- Patent Exclusivity & Biosimilar Entry: The composition of matter patent for Brodalumab is likely to expire by 2028, with biosimilar competition anticipated thereafter, exerting downward pressure on list prices.
- Market Competition: Increased utilization of biosimilars and competition from other IL-17 and IL-23 inhibitors (e.g., Guselkumab, Risankizumab) will trigger price adjustments to maintain market share.
- Value-Based Pricing: Payer shifts toward value-based contracts and outcome-based reimbursements could affect net pricing, incentivizing real-world effectiveness.
- Manufacturing & Regulatory Costs: The high costs associated with biologics maintenance, compliance, and production could stabilize or modestly increase list prices if innovation or manufacturing efficiencies are realized.
Future Market and Price Projections (2023-2030)
2023–2025: Stabilization Phase
In the near term, Brodalumab’s list price is expected to remain relatively stable, averaging $7,200/month. Payer negotiators will push for rebates to improve formulary positioning, leading to net prices declining to approximately $4,800/month over this period.
Sales growth will be driven by increased physician familiarity, expanded labeling (if applicable), and strategic marketing emphasizing efficacy in refractory cases. The market share remains limited relative to dominant agents, hence revenue growth is modest initially.
2026–2028: Patent Expiration & Biosimilar Introduction
Patent expiry around 2028 will catalyze significant price reductions, with biosimilars entering the market. List prices for biosimilars could be 30-50% lower than originator prices, with net prices decreasing further due to aggressive discounting.
Importantly, the transition period will involve negotiated discounts, rebates, and possible co-pay assistance programs to retain patient access and market share.
2029–2030: Competitive Equilibrium
Post-biosimilar entry, the biologic market for Brodalumab could experience a 15-35% price decline, with net prices settling around $2,500 to $3,500/month. Payers will prioritize cost-effective biosicrems, possibly relegating Brodalumab to niche indications or refractory patient populations.
Innovations in formulations, such as extended dosing intervals or fixed-dose combinations, may mitigate some price declines by improving adherence and reducing total treatment costs.
Implications for Stakeholders
- Pharmaceutical Manufacturers: Should prepare for a substantial decline in price and revenue post-biosimilar entry, with alternative revenue streams through lifecycle management or label expansion.
- Payers and Insurers: Will leverage formulary negotiations and value-based contracts to balance patient access with cost containment.
- Healthcare Providers: Need to consider cost-effectiveness, safety profiles, and patient preferences amid evolving pricing and competition.
Key Takeaways
- Market positioning of Brodalumab is currently stable but faces impending pricing pressure from biosimilar competition anticipated around 2028.
- List prices are approximately $7,200/month, with net prices likely around $4,800/month owing to rebates and discounts.
- Market growth will be constrained in the short term by safety concerns and competition, but long-term prospects depend heavily on biosimilar entry and pricing strategies.
- Strategic considerations include adopting value-based contracts, optimizing patient selection, and planning for lifecycle management post-patent expiry.
- Stakeholders should monitor regulatory developments, biosimilar market dynamics, and payer policies to adapt to upcoming market shifts.
FAQs
1. When is Brodalumab’s patent set to expire, and how will it impact pricing?
Patent expiry is projected around 2028, leading to biosimilar competition that could reduce list prices by 30-50%, significantly impacting revenue and market dynamics.
2. How does Brodalumab compare in efficacy and safety with other IL-17 inhibitors?
Brodalumab demonstrates comparable efficacy with a rapid onset. However, its boxed warning regarding suicidal ideation influences prescribing, safety considerations, and market share relative to competitors like Secukinumab and Ixekizumab.
3. What factors influence net pricing negotiations for Brodalumab?
Rebate strategies, formulary placement, payer negotiations, patient assistance programs, and safety profiles all determine final net prices.
4. Are there niche indications where Brodalumab’s pricing might remain stable longer?
Yes. In refractory or intolerant patients unresponsive to other biologics, clinicians may maintain utilization, potentially sustaining higher prices temporarily.
5. How will the evolving competitive landscape affect the overall market for inflammatory biologics?
Increased biosimilar presence and alternative mechanisms of action will foster price competition, potentially driving down costs but also prompting innovation in formulation and access strategies.
References
[1] U.S. Food and Drug Administration. Brodalumab prescribing information. 2017.
[2] IQVIA. U.S. biologic market data. 2023.
[3] MarketResearch.com. Biologics for psoriasis market report. 2022.
[4] EvaluatePharma. World Preview – Outlook to 2028. 2023.
[5] Centers for Medicare & Medicaid Services. Biosimilar policy updates. 2022.
Note: All data and projections are estimates based on current market conditions and available information as of early 2023. Actual market dynamics are subject to change based on regulatory, clinical, and economic factors.
